1. Scrip
  2. >>Business

Piramal Primes Hospital Injectables Play Via Janssen Products

 
• By Anju Ghangurde

Piramal is continuing on its acquisitive spree, snapping up a basket of injectable products from Janssen that are expected to give the diversified Indian group a foothold in the $20bn-plus global generic injectable hospital drugs market.

Piramal Enterprises Ltd. (PEL) has acquired five anesthesia and pain management injectable products from Janssen Pharmaceutica NV, in an all-cash deal. The transaction entails an upfront consideration of $155m and up to an additional $20m due to Janssen provided the portfolio achieves certain financial milestones over the next 30 months.

The deal marks the diversified Indian group's sixth healthcare acquisition in the last 24 months; the group has pumped in around INR18bn ($270m) towards inorganic growth over the past two years in the healthcare space

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Merck’s Welireg Adrenal Tumor Rollout Targets Specialized Centers

 
• By Alaric DeArment

The drugmaker won US FDA approval for the HIF-2α inhibitor in pheochromocytoma and paraganglioma, a rare cancer of the adrenal glands, in adolescents and adults.

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

 
• By Cathy Kelly

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.

Merck KGaA Braces For Volatility But Does Not Expect Europe To Budge On Pricing

 
• By Andrew McConaghie

Shares are hit as German conglomerate lowers revenue forecast.